Massachusetts biotech company Moderna launched Phase 3 of its coronavirus vaccine trial on Monday.
Moderna anticipates enrolling 30,000 U.S. participants.
MODERNA GETS FURTHER $472M US AWARD FOR CORONAVIRUS VACCINE DEVELOPMENT
There’s still no guarantee that the experimental vaccine, developed by the National Institutes of Health and Moderna Inc., will really protect.
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| MRNA | MODERNA INC. | 73.21 | -2.12 | -2.81% |
The needed proof: Volunteers won’t know if they’re getting the real shot or a dummy version. After two doses, scientists will closely track which group experiences more infections as they go about their daily routines, especially in areas where the virus still is spreading unchecked.
Moderna is working with the NIH and BARDA to develop its vaccine as part of Operation Warp Speed, the Trump administration’s effort to pinpoint and accelerate the most effective coronavirus vaccines.
